medigraphic.com
ISSN 2078-7170 (Digital)

2021, Número 3

<< Anterior Siguiente >>

CorSalud 2021; 13 (3)


Diabetes mellitus tipo 2: Consideraciones sobre riesgo y rehabilitación cardiovasculares. Segunda parte

Pérez YLM, Gutiérrez LA, Rodríguez BS

Idioma: Español
Referencias bibliográficas: 70
Paginas: 348-360
Archivo PDF: 337.63 Kb.


RESUMEN

La diabetes mellitus tipo 2 se asocia a un incremento del riesgo de mortalidad por enfermedad cardiovascular y es una afección frecuente dentro de los pacientes con enfermedad cardiovascular establecida. El tratamiento adecuado permite mejorar la calidad de vida del paciente y disminuir la morbilidad y la mortalidad por esta y otras causas. La rehabilitación cardiovascular ha demostrado ser una terapéutica eficaz y beneficiosa en los pacientes con diabetes mellitus tipo 2. Por eso, se revisaron 70 referencias bibliográficas con el objetivo de describir elementos importantes sobre su tratamiento, que incluye estrategias farmacológicas, no farmacológicas y la rehabilitación cardiovascular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Standards of Medical Care in Diabetes-2017: Sum-mary of Revisions. Diabetes Care. 2017;40(Supl 1):S4-5. [DOI]

  2. Piepoli MF, Hoes AW, Agewall S, Albus C, Bro-tons C, Catapano AL, et al. Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2016;69(10): 939. e1-87. [DOI]

  3. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, et al. Ef-fects of Mediterranean-style diet on glycemic con-trol, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analy-sis. Eur J Clin Nutr. 2015;69(11):1200-8. [DOI]

  4. Wycherley TP, Clifton PM, Noakes M, Brinkworth GD. Weight loss on a structured hypocaloric diet with or without exercise improves emotional dis-tress and quality of life in overweight and obese patients with type 2 diabetes. J Diabetes Investig. 2014;5(1):94-8. [DOI]

  5. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary com-ponents and nutritional strategies. Lancet. 2014; 383(9933):1999-2007. [DOI]

  6. Dempsey PC, Larsen RN, Sethi P, Sacre JW, Straz-nicky NE, Cohen ND, et al. Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of Light Walking or Simple Resistance Ac-tivities. Diabetes Care. 2016;39(6):964-72. [DOI]

  7. Way KL, Hackett DA, Baker MK, Johnson NA. The Effect of Regular Exercise on Insulin Sensitivity in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Metab J. 2016;40(4): 253-71. [DOI]

  8. Kim DY, Seo BD, Kim DJ. Effect of walking exer-cise on changes in cardiorespiratory fitness, met-abolic syndrome markers, and high-molecular-weight adiponectin in obese middle-aged women. J Phys Ther Sci. 2014;26(11):1723-7. [DOI]

  9. Tokmakidis SP, Touvra AM, Douda HT, Smilios I, Kotsa K, Volaklis KA. Training, detraining, and re-training effects on glycemic control and physical fitness in women with type 2 diabetes. Horm Me-tab Res. 2014;46(13):974-9. [DOI]

  10. Mendes R, Sousa N, Almeida A, Subtil P, Guedes-Marques F, Reis VM, et al. Exercise prescription for patients with type 2 diabetes-a synthesis of in-ternational recommendations: narrative review. Br J Sports Med. 2016;50(22):1379-81. [DOI]

  11. Harmer AR, Elkins MR. Amount and frequency of exercise affect glycaemic control more than exer-cise mode or intensity. Br J Sports Med. 2015; 49(15):1012-4. [DOI]

  12. Mangiamarchi P, Caniuqueo A, Ramírez-Campillo R, Cárdenas P, Morales S, Cano-Montoya J, et al. Ejercicio intermitente y consejería nutricional mejoran control glicémico y calidad de vida en pacientes con diabetes mellitus tipo 2. Rev Med Chile. 2017;145(7):845-53. [DOI]

  13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylu-reas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-53.

  14. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deed-wania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: im-plications of the ACCORD, ADVANCE, and VADT diabetes trials: a position statement of the Ameri-can Diabetes Association and a scientific state-ment of the American College of Cardiology Foun-dation and the American Heart Association. Dia-betes Care. 2009;32(1):187-92. [DOI]

  15. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Ef-fects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17): 1575-85. [DOI]

  16. American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Med-ical Care in Diabetes-2018. Diabetes Care. 2018; 41(Supl 1):S86-104. [DOI]

  17. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardio-vascular Disease: A Report of the American Col-lege of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circu-lation [Internet]. 2019 [citado 11 Oct 2020];140(11): e596-e646. Disponible en: https://doi. org/10. 1161/cir. 0000000000000678

  18. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Up-date. Can J Diabetes. 2016;40(6):484-6. [DOI]

  19. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Harper W, Clement M, Goldenberg R, Hanna A, Main A, et al. Phar-macologic management of type 2 diabetes. Can J Diabetes. 2013;37 (Suppl 1):S61-8. [DOI]

  20. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medi-cations as Monotherapy or Metformin-Based Com-bination Therapy for Type 2 Diabetes: A System-atic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740-51. [DOI]

  21. Griffin SJ, Leaver JK, Irving GJ. Impact of metfor-min on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 dia-betes. Diabetologia. 2017;60(9):1620-9. [DOI]

  22. Drug Safety and Availability. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Drug [In-ternet]. 2017 [citado 15 Oct 2020]. Disponible en: https://www. fda. gov/Drugs/DrugSafety/ucm493244. htm

  23. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hy-perglycemia in Type 2 Diabetes, 2018. A Consen-sus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12): 2669-701. [DOI]

  24. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, et al. Effects on the inci-dence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97. [DOI]

  25. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacologi-cal Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-34. [DOI]

  26. Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2097-9. [DOI]

  27. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1092-4. [DOI]

  28. Novo Nordisk. Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee [Internet]. 2017. Disponible en: https://www. reuters. com/article/brief-novo-nordisk-says-semaglutide-rece/brief-novo-nordisk-says-semaglutide-receives-positive-16-0-vote-in-favour-of-approval-from-fda-advisory-committee-idINFWN1MT0TA

  29. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-39. [DOI]

  30. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardio-vascular Outcomes in Patients with Type 2 Diabe-tes. N Engl J Med. 2016;375(19):1834-44. [DOI]

  31. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Ger-stein HC, Køber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syn-drome. N Engl J Med. 2015;373(23):2247-57. [DOI]

  32. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, et al. Effects of empagli-flozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39(5):363-70. [DOI]

  33. Marso SP, Daniels GH, Brown-Frandsen K, Kris-tensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabe-tes. N Engl J Med. 2016;375(4):311-22. [DOI]

  34. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Da-vidson J, Hirshberg B, et al. Saxagliptin and car-diovascular outcomes in patients with type 2 dia-betes mellitus. N Engl J Med. 2013;369(14):1317-26. [DOI]

  35. White WB, Cannon CP, Heller SR, Nissen SE, Ber-genstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabe-tes. N Engl J Med. 2013;369(14):1327-35. [DOI]

  36. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Car-diovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. [DOI]

  37. McMurray JJV, Ponikowski P, Bolli GB, Luka-shevich V, Kozlovski P, Kothny W, et al. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018;6(1):8-17. [DOI]

  38. Moura CS, Rosenberg ZB, Abrahamowicz M, Ber-natsky S, Behlouli H, Pilote L. Treatment Discon-tinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 In-hibitors or NPH Insulin as Third-Line Therapy. J Diabetes Res [Internet]. 2018 [citado 20 Oct 2020]; 2018:4817178. Disponible en: https://doi. org/10. 1155/2018/4817178

  39. McMurray JJV, Ponikowski P, Bolli GB, Lukashe-vich V, Kozlovski P, Kothny W, et al. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018;6(1):8-17. [DOI]

  40. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10): 1180-8. [DOI]

  41. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-95. [DOI]

  42. American College of Cardiology. Effect of Ranola-zine in Type 2 Diabetes: Evaluation of Its Use Be-yond Chronic Stable Angina. [Internet] 2017. [ci-tado 23 Oct 2020] Disponible en: https://www. acc. org/latest-in-cardiology/articles/2017/06/01/16/10/effect-of-ranolazine-in-type-2-diabetes

  43. Brown RA. Rehabilitation of patients with cardio-vascular diseases. Report of a WHO Expert Com-mittee. World Health Organ Tech Rep Ser. 1964; 270:3-46.

  44. López Jiménez F, Pérez-Terzic C, Zeballos PC, Anchique CV, Burdiat G, González K, et al. Con-senso de RCV y Prevención Secundaria de las Sociedades Interamericana y Sudamericana de Cardiología. Rev Urug Cardiol. 2013;28(2):189-224.

  45. Acevedo M, Kramer V, Bustamante MJ, Yáñez F, Guidi D, Corbalán R, et al. Rehabilitación cardiovascular y ejercicio en prevención secundaria. Rev Med Chile. 2013;141(10):1307-14. [DOI]

  46. Sociedad Argentina de Cardiología. Consenso Argentino de Rehabilitación Cardiovascular. Rev Arg Card. 2019;87(3):1-57.

  47. Schwingshackl L, Missbach B, Dias S, König J, Hoffmann G. Impact of different training modali-ties on glycaemic control and blood lipids in pa-tients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014; 57(9):1789-97. [DOI]

  48. Liu Y, Liu SX, Cai Y, Xie KL, Zhang WL, Zheng F. Effects of combined aerobic and resistance train-ing on the glycolipid metabolism and inflamma-tion levels in type 2 diabetes mellitus. J Phys Ther Sci. 2015;27(7):2365-71. [DOI]

  49. Mendham AE, Duffield R, Marino F, Coutts AJ. A 12-week sports-based exercise programme for in-active Indigenous Australian men improved clini-cal risk factors associated with type 2 diabetes mellitus. J Sci Med Sport. 2015;18(4):438-43. [DOI]

  50. Little JP, Gillen JB, Percival ME, Safdar A, Tarno-polsky MA, Punthakee Z, et al. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol (1985). 2011;111(6):1554-60. [DOI]

  51. Alvarez C, Ramirez-Campillo R, Martinez-Salazar C, Mancilla R, Flores-Opazo M, Cano-Montoya J, et al. Low-Volume High-Intensity Interval Training as a Therapy for Type 2 Diabetes. Int J Sports Med. 2016;37(9):723-9. [DOI]

  52. Mancilla R, Torres P, Álvarez C, Schifferli I, Sa-punar J, Díaz E. High intensity interval training improves glycemic control and aerobic capacity in glucose intolerant patients. Rev Med Chil. 2014; 142(1):34-9. [DOI]

  53. Golbidi S, Badran M, Laher I. Antioxidant and anti-inflammatory effects of exercise in diabetic patients. Exp Diabetes Res [Internet]. 2012 [citado 28 Oct 2020];2012:941868. Disponible en: https://doi. org/10. 1155/2012/941868

  54. Verma S, Moiz JA, Anwer S, Alghadir AH, Hussain ME. A dose-response study of aerobic training for oxygen uptake, oxidative stress and cardiac au-tonomic function in type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials [Internet]. 2018 [citado 28 Oct 2020];19(1): 289. Disponible en: https://doi. org/10. 1186/s13063-018-2671-y

  55. Nishitani M, Shimada K, Sunayama S, Masaki Y, Kume A, Fukao K, et al. Impact of diabetes on muscle mass, muscle strength, and exercise tol-erance in patients after coronary artery bypass grafting. J Cardiol. 2011;58(2):173-80. [DOI]

  56. Huebschmann AG, Kohrt WM, Herlache L, Wolfe P, Daugherty S, Reusch JE, et al. Type 2 diabetes exaggerates exercise effort and impairs exercise performance in older women. BMJ Open Diabe-tes Res Care [Internet]. 2015 [citado 29 Oct 2020]; 3(1):e000124. Disponible en: https://doi. org/10. 1136/bmjdrc-2015-000124

  57. Innes KE, Selfe TK. Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Tri-als. J Diabetes Res [Internet]. 2016 [citado 29 Oct 2020];2016:6979370. Disponible en: https://doi. org/10. 1155/2016/6979370

  58. Ahn S, Song R. Effects of Tai Chi Exercise on glu-cose control, neuropathy scores, balance, and quality of life in patients with type 2 diabetes and neuropathy. J Altern Complement Med. 2012; 18(12):1172-8. [DOI]

  59. Jiménez-Navarro MF, Lopez-Jimenez F, Pérez-Belmonte LM, Lennon RJ, Diaz-Melean C, Rodri-guez-Escudero JP, et al. Benefits of Cardiac Reha-bilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coro-nary Intervention. J Am Heart Assoc [Internet]. 2017 [citado 1 Nov 2020];6(10):e006404. Disponi-ble en: https://doi. org/10. 1161/jaha. 117. 006404

  60. Choe Y, Han JY, Choi IS, Park HK. Improvement of exercise capacity in patients with type 2 diabe-tes mellitus during cardiac rehabilitation. Eur J Phys Rehabil Med. 2018;54(6):981-3. [DOI]

  61. Toste S, Viamonte S, Barreira A, Fernandes P, Lo-pes Gomes J, Torres S. Cardiac rehabilitation in patients with type 2 diabetes mellitus and coro-nary disease: a comparative study. Rev Port Car-diol. 2014;33(10):599-608. [DOI]

  62. St Clair M, Mehta H, Sacrinty M, Johnson D, Rob-inson K. Effects of cardiac rehabilitation in diabet-ic patients: both cardiac and noncardiac factors determine improvement in exercise capacity. Clin Cardiol. 2014;37(4):233-8. [DOI]

  63. Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis. Int J Behav Nutr Phys Act [Internet]. 2014 [citado 2 Nov 2020];11:2. Dis-ponible en: https://doi. org/10. 1186/1479-5868-11-2

  64. Gómez-González A, Calderín GM, Pleguezuelos Cobos E, Expósito Tirado JA, Heredia Torres A, Montiel Trujillo, et al. Recomendaciones sobre rehabilitación cardíaca en la cardiopatía isquémi-ca de la Sociedad de Rehabilitación Cardio-Respi-ratoria (SORECAR). Rehabilitación (Madr). 2015; 49(2):102-24. [DOI]

  65. Lopez-Jimenez F, Kramer VC, Masters B, Stuart PM, Mullooly C, Hinshaw L, et al. Recommenda-tions for managing patients with diabetes mellitus in cardiopulmonary rehabilitation: an American Association of Cardiovascular and Pulmonary Rehabilitation statement. J Cardiopulm Rehabil Prev. 2012;32(2):101-12. [DOI]

  66. Jaureguizar KV, Vicente-Campos D, Bautista LR, de la Peña CH, Gómez MJ, Rueda MJ, et al. Effect of High-Intensity Interval Versus Continuous Ex-ercise Training on Functional Capacity and Quali-ty of Life in Patients With Coronary Artery Dis-ease: A RANDOMIZED CLINICAL TRIAL. J Car-diopulm Rehabil Prev. 2016;36(2):96-105. [DOI]

  67. Terada T, Boulé NG, Forhan M, Prado CM, Kenny GP, Prud'homme D, et al. Cardiometabolic risk factors in type 2 diabetes with high fat and low muscle mass: At baseline and in response to ex-ercise. Obesity (Silver Spring). 2017;25(5):881-91. [DOI]

  68. Borg GA. Psychophysical bases of perceived ex-ertion. Med Sci Sports Exerc. 1982;14(5):377-81.

  69. Lopez-Jimenez F, Kramer VC, Masters B, Stuart PM, Mullooly C, Hinshaw L, et al. Recommenda-tions for managing patients with diabetes mellitus in cardiopulmonary rehabilitation: an American Association of Cardiovascular and Pulmonary Rehabilitation statement. J Cardiopulm Rehabil Prev. 2012;32(2):101-12. [DOI]

  70. Hollekim-Strand SM, Bjørgaas MR, Albrektsen G, Tjønna AE, Wisløff U, Ingul CB. High-intensity in-terval exercise effectively improves cardiac func-tion in patients with type 2 diabetes mellitus and diastolic dysfunction: a randomized controlled trial. J Am Coll Cardiol. 2014;64(16):1758-60. [DOI]




2020     |     www.medigraphic.com